Table 1. Benign Prostatic Hyperplasia Drugs Consumption Value & CAGR: China VS Global, 2018-2029, US$ Million

Table 2. Benign Prostatic Hyperplasia Drugs Market Restraints

Table 3. Benign Prostatic Hyperplasia Drugs Market Trends

Table 4. Benign Prostatic Hyperplasia Drugs Industry Policy

Table 5. Global Benign Prostatic Hyperplasia Drugs Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022

Table 6. Global Benign Prostatic Hyperplasia Drugs Revenue Share by Company, 2018-2023, Ranked by Data of 2022

Table 7. Global Benign Prostatic Hyperplasia Drugs Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Benign Prostatic Hyperplasia Drugs Mergers & Acquisitions, Expansion Plans

Table 9. Global Benign Prostatic Hyperplasia Drugs Major Companies Product Type

Table 10. Head Office and Area Served of Key Players

Table 11. China Benign Prostatic Hyperplasia Drugs Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022

Table 12. China Benign Prostatic Hyperplasia Drugs Revenue Market Share by Company, 2018-2023

Table 13. Global Key Players of Benign Prostatic Hyperplasia Drugs Upstream (Raw Materials)

Table 14. Global Benign Prostatic Hyperplasia Drugs Typical Customers

Table 15. Benign Prostatic Hyperplasia Drugs Typical Distributors

Table 16. By Type, Global Benign Prostatic Hyperplasia Drugs Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 17. By Application, Global Benign Prostatic Hyperplasia Drugs Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 18. By Region, Global Benign Prostatic Hyperplasia Drugs Consumption Value, 2018 VS 2022 VS 2029, US$ Million

Table 19. By Region, Global Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Table 20. By Country, Global Benign Prostatic Hyperplasia Drugs Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 21. By Country, Global Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Table 22. By Country, Global Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2018-2029

Table 23. Sanofi Company Information, Head Office, Market Area and Industry Position

Table 24. Sanofi Company Profile and Main Business

Table 25. Sanofi Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 26. Sanofi Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 27. Sanofi Recent Developments

Table 28. Boehringer Ingelheim Company Information, Head Office, Market Area and Industry Position

Table 29. Boehringer Ingelheim Company Profile and Main Business

Table 30. Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 31. Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 32. Boehringer Ingelheim Recent Developments

Table 33. Maithili Life Sciences Company Information, Head Office, Market Area and Industry Position

Table 34. Maithili Life Sciences Company Profile and Main Business

Table 35. Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 36. Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 37. Maithili Life Sciences Recent Developments

Table 38. DM Pharma Company Information, Head Office, Market Area and Industry Position

Table 39. DM Pharma Company Profile and Main Business

Table 40. DM Pharma Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 41. DM Pharma Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 42. DM Pharma Recent Developments

Table 43. Teva Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

Table 44. Teva Pharmaceuticals Company Profile and Main Business

Table 45. Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 46. Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 47. Teva Pharmaceuticals Recent Developments

Table 48. Mylan Company Information, Head Office, Market Area and Industry Position

Table 49. Mylan Company Profile and Main Business

Table 50. Mylan Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 51. Mylan Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 52. Mylan Recent Developments

Table 53. Zydus Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

Table 54. Zydus Pharmaceuticals Company Profile and Main Business

Table 55. Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 56. Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 57. Zydus Pharmaceuticals Recent Developments

Table 58. Wockhardt Company Information, Head Office, Market Area and Industry Position

Table 59. Wockhardt Company Profile and Main Business

Table 60. Wockhardt Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 61. Wockhardt Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 62. Wockhardt Recent Developments

Table 63. Sun Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 64. Sun Pharmaceutical Company Profile and Main Business

Table 65. Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 66. Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 67. Sun Pharmaceutical Recent Developments

Table 68. Glenmark Pharmaceuticals Ltd. Company Information, Head Office, Market Area and Industry Position

Table 69. Glenmark Pharmaceuticals Ltd. Company Profile and Main Business

Table 70. Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 71. Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 72. Glenmark Pharmaceuticals Ltd. Recent Developments

Table 73. TRB Pharma S.A. Company Information, Head Office, Market Area and Industry Position

Table 74. TRB Pharma S.A. Company Profile and Main Business

Table 75. TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 76. TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 77. TRB Pharma S.A. Recent Developments

Table 78. Kunming Jida Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position

Table 79. Kunming Jida Pharmaceutical Co., Ltd. Company Profile and Main Business

Table 80. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 81. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 82. Kunming Jida Pharmaceutical Co., Ltd. Recent Developments

Table 83. Medzeel Lifescience Company Information, Head Office, Market Area and Industry Position

Table 84. Medzeel Lifescience Company Profile and Main Business

Table 85. Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 86. Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 87. Medzeel Lifescience Recent Developments

Table 88. Wellona Pharma Company Information, Head Office, Market Area and Industry Position

Table 89. Wellona Pharma Company Profile and Main Business

Table 90. Wellona Pharma Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 91. Wellona Pharma Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 92. Wellona Pharma Recent Developments

Table 93. Niksan Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 94. Niksan Pharmaceutical Company Profile and Main Business

Table 95. Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 96. Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 97. Niksan Pharmaceutical Recent Developments

Table 98. Lunan Pharmaceutical Group Corporation Company Information, Head Office, Market Area and Industry Position

Table 99. Lunan Pharmaceutical Group Corporation Company Profile and Main Business

Table 100. Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 101. Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 102. Lunan Pharmaceutical Group Corporation Recent Developments

Table 103. Zhejiang Xianju Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position

Table 104. Zhejiang Xianju Pharmaceutical Co.,Ltd. Company Profile and Main Business

Table 105. Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 106. Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 107. Zhejiang Xianju Pharmaceutical Co.,Ltd. Recent Developments

Table 108. Hunan Jiudian Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position

Table 109. Hunan Jiudian Pharmaceutical Co.,Ltd. Company Profile and Main Business

Table 110. Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 111. Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 112. Hunan Jiudian Pharmaceutical Co.,Ltd. Recent Developments

Table 113. Chengdu Brilliant Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position

Table 114. Chengdu Brilliant Pharmaceutical Co., Ltd. Company Profile and Main Business

Table 115. Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 116. Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 117. Chengdu Brilliant Pharmaceutical Co., Ltd. Recent Developments

Table 118. Guangdong Eashu Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position

Table 119. Guangdong Eashu Pharmaceutical Co.,Ltd. Company Profile and Main Business

Table 120. Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications, and Application

Table 121. Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, US$ Million, 2018-2023

Table 122. Guangdong Eashu Pharmaceutical Co.,Ltd. Recent Developments

List of Figures

Figure 1. Benign Prostatic Hyperplasia Drugs Picture

Figure 2. Global Benign Prostatic Hyperplasia Drugs Consumption Value, (US$ million) & (2018-2029)

Figure 3. China Benign Prostatic Hyperplasia Drugs Consumption Value, (US$ million) & (2018-2029)

Figure 4. By Consumption Value, China Benign Prostatic Hyperplasia Drugs Market Share of Global, 2018-2029

Figure 5. Global Benign Prostatic Hyperplasia Drugs Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2022

Figure 6. China Benign Prostatic Hyperplasia Drugs Key Participants, Market Share, 2022

Figure 7. Benign Prostatic Hyperplasia Drugs Industry Chain

Figure 8. Benign Prostatic Hyperplasia Drugs Procurement Model

Figure 9. Benign Prostatic Hyperplasia Drugs Sales Model

Figure 10. Benign Prostatic Hyperplasia Drugs Sales Channels, Direct Sales, and Distribution

Figure 11. Tamsulosin

Figure 12. Finasteride

Figure 13. Terazosin

Figure 14. Other

Figure 15. By Type, Global Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 16. By Type, Global Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2018-2029

Figure 17. Hospital

Figure 18. Clinic

Figure 19. Other

Figure 20. By Application, Global Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 21. By Application, Global Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2018-2029

Figure 22. By Region, Global Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2018-2029

Figure 23. North America Benign Prostatic Hyperplasia Drugs Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 24. By Country, North America Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022

Figure 25. Europe Benign Prostatic Hyperplasia Drugs Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 26. By Country, Europe Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022

Figure 27. Asia Pacific Benign Prostatic Hyperplasia Drugs Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 28. By Country/Region, Asia Pacific Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022

Figure 29. South America Benign Prostatic Hyperplasia Drugs Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 30. By Country, South America Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022

Figure 31. Middle East & Africa Benign Prostatic Hyperplasia Drugs Consumption Value & Forecasts, 2018-2029, US$ Million

Figure 32. U.S. Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 33. By Type, U.S. Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 34. By Application, U.S. Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 35. Europe Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 36. By Type, Europe Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 37. By Application, Europe Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 38. China Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 39. By Type, China Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 40. By Application, China Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 41. Japan Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 42. By Type, Japan Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 43. By Application, Japan Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 44. South Korea Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 45. By Type, South Korea Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 46. By Application, South Korea Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 47. Southeast Asia Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 48. By Type, Southeast Asia Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 49. By Application, Southeast Asia Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 50. India Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 51. By Type, India Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 52. By Application, India Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 53. Middle East & Africa Benign Prostatic Hyperplasia Drugs Consumption Value, 2018-2029, US$ Million

Figure 54. By Type, Middle East & Africa Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 55. By Application, Middle East & Africa Benign Prostatic Hyperplasia Drugs Consumption Value Market Share, 2022 VS 2029

Figure 56. Research Methodology

Figure 57. Breakdown of Primary Interviews

Figure 58. Bottom-up and Top-down Approaches

Figure 59. Top-down Approaches